A case of histoplasmosis, simulating a bronchogenic carcinoma, was needle biopsied. "Histoplasma capsulatum" organisms were found in great numbers. Needle biopsy established an accurate diagnosis making an exploratory thoracotomy unnecessary and preventing the patient from an already planned lobectomy. Specific treatment with Amphotericin B healed the lesion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2008-1056797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidental Mucinous Neoplasms of the Pancreas: Performance of the AGA, European, and IAP Guidelines in Advising Further Management after Endoscopic ultrasound-guided fine-needle Aspiration Biopsy.
Pancreas
January 2025
Digestive Endoscopy Service, Hospital Moriah, São Paulo, SP, Brazil.
Objectives: We compared the performance of AGA-2015, ESG-2018, and IAP-2024 guidelines in referring patients for surgery versus surveillance when applied to incidental after diagnosis by EUS-FNA.
Methods: Single-center, retrospective study with prospective data collection. PLs identified incidentally on CT or MRI/MRCP performed for other diseases with inconclusive imaging results were eligible for analysis.
Endoscopic ultrasound-guided biopsy of healthy pig pancreas - Towards the histological diagnosis of chronic pancreatitis.
Rev Esp Enferm Dig
September 2024
Gastroenterology, Hospital Clínico Universitario de Santiago.
Background: diagnosis of early chronic pancreatitis (CP) is a challenge due to the lack of accurate methods. The ability of endoscopic ultrasound (EUS) guided biopsy to obtain pancreatic core tissue samples in patients with minimal changes of CP and its potential use for the histological diagnosis of early CP are unknown. The aim of the study was to evaluate the ability of different EUS-guided biopsy core needles to obtain histological samples of healthy pig pancreas.
View Article and Find Full Text PDFEnabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
Nat Commun
January 2025
Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) can mediate tumor regression, including complete and durable responses, in a range of solid cancers, most notably in melanoma. However, its wider application and efficacy has been restricted by the limited accessibility, proliferative capacity and effector function of tumor-specific TIL. Here, we develop a platform for the efficient identification of tumor-specific TCR genes from diagnostic tumor biopsies, including core-needle biopsies frozen in a non-viable format, to enable engineered T cell therapy.
View Article and Find Full Text PDFRhabdomyosarcoma Surgical Update.
Pediatr Blood Cancer
January 2025
Division of Pediatric Surgery, Kentucky Children's Hospital, University of Kentucky, Lexington, Kentucky, USA.
Rhabdomyosarcoma (RMS) tumors arise from mesenchymal tissue and represent half of pediatric sarcomas, which in turn make up 7% of pediatric tumors. Advances in local control therapy of RMS have improved outcomes after surgical resection of the primary tumor, either before or after induction chemotherapy, even in the setting of metastatic disease. The utilization of diagnostic core needle and sentinel node biopsy techniques for lymph node staging are becoming more widely used.
View Article and Find Full Text PDFBackground: Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of peripheral T-cell lymphoma (PTCL) and accounts for 2% of all non-Hodgkin lymphomas. Its typical characteristics include an aggressive course, progressive lymphadenopathy, hepatosplenomegaly, systemic symptoms, anemia, hypergammaglobulinemia, and generally poor prognosis.
Methods: We describe a rare case in which the left inguinal lymph node was completely excised and biopsied one year ago.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!